Leader of this group:
MD, PhD Camilla Tøndel
Camilla Tøndel has since 2001 been responsible for follow up of young pasients with Fabry disease and in 2013 she finalized her PhD on nephropathy in young Fabry disease patients with focus on kidney biopsies and functional measurements. Since 2015 she has been 50 % post doc studying renal functional and structural aspects in young patients with chronic kidney disease.
She is since 2011 headig the hospitals pediatric clinical trials unit doing a high number of pediatric clinical trials as well as clinical trials on new treatments for Fabry disease including first in human gene therapy. She is associate editor in Clinical Kidney Journal, in the steering group of NorPedMed and deputy leader in the NorCRIN-board.
Renal functional and structural aspects in young patients with Fabry disease has been studied since more than 15 years together with The Renal Research Group, University of Bergen, and there is today broad international collaboration with long term follow-up studies, experimental research and clinical trials on new treatment approches on Fabry disease including first in human gene therapy.
During the last ten years methodological research on renal function in children with chronic kidney disease has given important knowledge on GFR-methodology changing the methods used for measuring kidney function in children in Norwegian hospitals. Follow-up GFR-studies and further methodologic studies are important collaborative projects.
Within pediatric rheumatology there is broad international and national collaboration with Eurofever Registry by Pediatric Reumatology Inter National Trials Organisation and Pediatric Rheumatology European Society, revision of International League Against Rheumatism (ILAR) criteria as well as interventional studies in collaboration with pediatric radiology and odontology. There is important collaboration with The Research Group of Immunology and Reumatology, UiB, including PhD in 2018 on biomarkers in early rheumatoid artritis.